Skip to main content
. 2014 May 15;14:335. doi: 10.1186/1471-2407-14-335

Table 1.

Demographics and the distribution of IDO expression

Variable Total N (%) IDO expression
Mean P-value
Age, years
121
 
 
<50
85 (70.2)
7.0
<0.001
≥50
36 (29.8)
20.2
 
Sex
121
 
 
Female
41 (33.9)
7.4
<0.001
Male
80 (66.1)
12.8
 
Histologic subtype
121
 
 
NLP
5 (4.1)
3.3
<0.001
NS
64 (52.9)
5.8
 
MC
46 (38.0)
19.2
 
LD
1 (0.8)
15.6
 
LR
1 (0.8)
1.1
 
Unclassifiable
4 (3.3)
8.9
 
Ann Arbor stage
115
 
 
I-II
66 (57.4)
6.9
0.004
III-IV
49 (42.6)
17.3
 
B symptoms
107
 
 
Yes
34 (31.8)
16.2
0.454
No
73 (68.2)
9.1
 
Bulky disease
104
 
 
Yes
8 (7.7)
11.8
0.826
No
96 (92.3)
11.8
 
IPS
116
 
 
≤2
82 (70.7)
7.5
0.013
>2
34 (29.3)
20.6
 
EBV status
96
 
 
Positive
43 (44.8)
17.4
0.069
Negative
53 (55.2)
8.7
 
HIV status
121
 
 
Positive
3 (2.5)
58.6
0.001
Negative
118 (97.5)
9.7
 
Treatment response
98
 
 
Success
65 (66.3)
10.0
0.098
Relapse
21 (21.4)
11.0
 
Progression 12 (12.2) 26.4  

IDO, indoleamine 2,3-dioxygenase; NLP, nodular lymphocyte predominant; NS, nodular sclerosis; MC, mixed cellularity; LR, lymphocyte-rich; LD, lymphocyte-depleted; IPS, international prognostic score.

HHS Vulnerability Disclosure